Arrowhead CEO Says Calando Will Focus All of Its Efforts on Lead RNAi Cancer Rx

Earlier this year, Arrowhead announced that it had closed Calando’s laboratory and shifted all its development efforts onto another of its subsidiaries. But with this week’s announcement, it appears that Arrowhead has decided to give its lead RNAi cancer therapeutic a second chance.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.